🧬 Aging Wiki

irf7

Properties1
aliasesinterferon regulatory factor 7, IRF-7

12 min read

IRF7 (Interferon Regulatory Factor 7)

Master transcriptional regulator of type I interferon responses, with a central role in innate antiviral immunity. IRF7 is constitutively and highly expressed in plasmacytoid dendritic cells (pDCs) — the dominant producers of IFN-α — and is itself an interferon-stimulated gene (ISG), enabling a feed-forward amplification loop. In aging, stimulus-evoked pDC IFN-α production declines with physical frailty 1, while simultaneously, general pro-inflammatory cytokine tone increases — an uncoupling pattern that may underlie elevated influenza mortality in the elderly. In aged mice, early type I IFN responses to influenza are blunted but late-phase inflammatory activity is elevated 2. The concept that IRF7-mediated IFN amplification is non-redundant for human antiviral defense is established by inborn-error genetics 34.

Identity

  • UniProt: Q92985 (IRF7_HUMAN)
  • NCBI Gene: 3665
  • HGNC: 6122 · symbol: IRF7
  • Ensembl: ENSG00000185507
  • Chromosomal location: 11p15.5
  • Mouse ortholog: Irf7 (one-to-one; high sequence conservation of the DNA-binding and signal-response domains)
  • Length: 503 amino acids (canonical isoform)

Domain architecture

IRF7 is a member of the IRF (interferon regulatory factor) family, characterized by an N-terminal winged-helix DNA-binding domain (DBD) that contacts interferon-stimulated response elements (ISREs) via a conserved tryptophan pentad repeat 5.

Key functional regions (approximate residue boundaries):

DomainResiduesFunction
DNA-binding domain (DBD)~11–126Tryptophan pentad; ISRE-contact; recognized as IRF/SMAD-like fold
Linker / disordered regions69–88, 133–156, 242–277Flexible interdomain segments
IRF association domain (IAD) / signal-response domain~200–450Autoinhibitory in resting state; site of C-terminal phosphorylation; mediates homo- and heterodimerization
NMI interaction region284–456Interaction with NMI (N-Myc interactor)

Resting-state autoinhibition: In unstimulated cells, IRF7 adopts a closed conformation in which the IAD occludes the DBD, holding the protein inactive as a cytoplasmic monomer 5. Phosphorylation of multiple C-terminal serines disrupts this autoinhibition, exposing the DBD and dimerization surfaces.

Activation mechanism: TBK1/IKKε phosphorylation

Upon viral sensing (via TLR7, TLR9, RIG-I, MDA5, cGAS-STING depending on cell type), the kinases TBK1 and IKKε (IKBKE) phosphorylate IRF7 at multiple C-terminal serine residues 5. The primary activating sites confirmed by UniProt are:

  • Ser-477 — phosphorylated by TBK1 and IKKε
  • Ser-479 — phosphorylated by TBK1 and IKKε

Additional contributing sites include Ser-471, Ser-472, Ser-475, Ser-483, Ser-484, and Ser-487. Phosphorylation at the Ser-477/479 cluster appears to be the minimal requirement for conformational opening and nuclear import 5.

After phosphorylation, IRF7 forms homodimers (IRF7:IRF7) or heterodimers with irf3 (IRF7:IRF3), translocates to the nucleus, and drives transcription of IFNA genes (multiple subtypes) and, to a lesser extent, IFNB1 3.

IRF7 vs IRF3 specificity: IRF3 is the primary driver of IFNB1 (IFN-β) transcription in most cell types and is ubiquitously expressed. IRF7, by contrast, preferentially drives transcription of multiple IFNA gene subtypes and is required for robust IFN-α production. This division of labor is most evident in pDCs (see below) and in secondary/amplified IFN responses 3.

Inhibitory PTMs

  • Lys-92 acetylation (by KAT2A/GCN5 and KAT2B/PCAF) — inhibits DNA-binding.
  • Lys-444/446 sumoylation (by TRIM28/KAP1) — inhibits transactivation.
  • Lys-375 K63-ubiquitination (by NEURL3) — promotes activation (atypical ubiquitin linkage; activates rather than degrades).

These PTM layers allow fine-tuned signal integration, balancing antiviral amplification against inflammatory runaway.

pDC-specific constitutive expression

In virtually all somatic cell types, IRF7 protein is present at low basal levels and is induced only after initial type I IFN signaling. Plasmacytoid dendritic cells (pDCs) are the principal exception: they maintain constitutively high IRF7 protein, attributable to tonic IRF activity from their differentiation program 3. This pre-loaded state enables pDCs to produce massive amounts of IFN-α within hours of TLR7 or TLR9 engagement — up to 1000-fold more IFN-α per cell than other immune cell types. needs-replication — the precise fold-excess figure depends heavily on stimulus and cell isolation protocol.

Feed-forward amplification loop

IRF7 is itself an interferon-stimulated gene (ISG): its promoter contains ISRE elements occupied by ISGF3 (STAT1:STAT2:IRF9 complex) following initial type I IFN signaling. Accordingly, once early IFN-β (IRF3-driven) or initial pDC-derived IFN-α engages the type-i-interferon-signaling pathway in autocrine/paracrine fashion, IRF7 expression is upregulated in neighboring cells, enabling them to mount a secondary wave of IFN-α production 3.

This architecture explains why IRF7 deficiency specifically impairs the amplified IFN response rather than completely abolishing it: the initial, IRF3-driven IFN-β pulse is partially preserved; it is the exponential amplification that fails.

Aging context

pDC-driven tonic IFN-α and inflammaging

In older individuals, a paradoxical dual dysregulation emerges:

  1. Impaired stimulus-evoked pDC IFN-α production correlates with frailty: Cross-sectional data in Japanese elderly (n=141, ages 65+, excluding those with chronic diseases) show that the proportion of IFN-α-producing pDCs (IFN-α+pDC, measured after H1N1 stimulation) decreases with progression to physical frailty: median IFN-α+pDC 3.45% (IQR 1.19–6.06) in robust vs 1.85% (IQR 0.78–2.25) in frail participants. Logistic regression (model 2, adjusted for age, sex, influenza vaccination, influenza history, cold frequency, and allergies) found an OR of 0.212 (95% CI 0.051–0.895, p=0.04) for high IFN-α+pDC levels in the frail vs robust group 1. The direction is unambiguously a decline in pDC IFN-α secretory function with frailty — not an excess. needs-replication (cross-sectional; no longitudinal data; frail group n=13 is small)

  2. Elevated pro-inflammatory cytokines with frailty: Separately from pDC IFN-α, frail participants in the same cohort tended to have higher serum IL-1β, IL-6, TNF-α, and MIG concentrations compared to robust participants 1. This pro-inflammatory cytokine pattern reflects general inflammaging but is distinct from pDC-IFN-α function.

  3. Impaired early type I IFN responses in aged mice: In old (70-week) vs young (12-week) C57BL/6J mice infected intranasally with influenza A PR8, aged mice showed significantly lower type I IFN expression in the lung at 3 days post-infection (dpi), alongside higher viral loads 2. By contrast, type III IFN was elevated in aged mice at 3 dpi and correlated with higher viral load. At 7 dpi, scRNA-seq revealed elevated expression of Irf7, Ddx58, Il6, and Tnf across macrophages, monocytes, NK cells, dendritic cells, and granulocytes in old mice, suggesting late-phase sustained inflammatory activation rather than simple loss of IRF7. The early IFN deficit appears to be a timing/kinetics defect rather than a loss of IRF7 protein. no-mechanism — the molecular basis for early type I IFN impairment is not established in this study.

Aging effectDirectionNotes
Stimulus-evoked pDC IFN-α (H1N1-stimulated)decreased with frailtyOR 0.212 (95% CI 0.051–0.895) for high IFN-α+pDC in frail vs robust 1; n=13 frail, n=76 robust
Pro-inflammatory serum cytokines (IL-1β, IL-6, TNF-α, MIG)increased with frailty1; general inflammaging signal
Early type I IFN lung expression (3 dpi, mouse)decreasedAged 70-wk vs young 12-wk C57BL/6J; higher viral load in old mice 2
Late Irf7 mRNA in lung immune cells (7 dpi, mouse)increasedscRNA-seq; sustained late-phase inflammation 2
IRF7 protein level in aged human pDCsunclearNot directly measured in either cited study needs-replication

Physical frailty correlation: A 2026 cross-sectional study in Japanese elderly (Sugihara et al., Immunity & Ageing, n=141, mean age 79.5±5.3 years, excluding those with chronic diseases) found that stimulus-evoked IFN-α production by pDCs declines with physical frailty progression 1. The causal direction (whether frailty drives pDC dysfunction or vice versa) is not established, and the small frail group (n=13) warrants cautious interpretation. no-mechanism

IRF7 loss-of-function and infection mortality: inborn-error lessons

Casanova and colleagues established in 2015 that compound-heterozygous null mutations in IRF7 cause life-threatening influenza pneumonitis in an otherwise healthy child with no other immune defect 3. The index patient had markedly impaired type I and III IFN amplification; the patient’s leukocytes and pDCs produced very little type I and III IFN in response to influenza virus, while dermal fibroblasts and iPSC-derived pulmonary epithelial cells produced reduced amounts of type I IFN and showed increased viral replication. The paper established compound-heterozygous (not homozygous) inheritance in this single index case.

This inborn-error model is directly relevant to aging in two ways:

  • As a phenocopy of aged innate immunity: The IRF7-deficient patient’s impaired IFN amplification mirrors — mechanistically — the age-associated decline in pDC IFN-α responses, even though the underlying cause is genetic rather than epigenetic/degenerative.
  • As a human proof-of-concept for the IFN-amplification bottleneck: Elevated influenza mortality in the elderly (~90% of seasonal influenza deaths occur in people ≥65) is not fully explained by adaptive immunity — the innate IFN response kinetics are a substantial contributor 2.
DimensionStatusNotes
Pathway conserved in humans?yesIRF7-TBK1-IFN-α axis is conserved; mouse Irf7 knockout phenocopies human IRF7 deficiency
Phenotype conserved in humans?yesHuman loss-of-function established 3
Replicated in humans?yes (genetics)Multiple Casanova-lab patients; COVID-19 loss-of-function data also confirms 4

COVID-19 connection

Zhang et al. (2020, Science, n=659 critically ill COVID-19 pneumonia vs 534 asymptomatic/mild controls) found that deleterious variants in TLR3- and IRF7-dependent type I IFN pathway genes are enriched in patients with life-threatening COVID-19 4. IRF7 was specifically listed among the eight genes with deleterious variants; 8 patients carried IRF7 variants (including both autosomal-recessive and autosomal-dominant forms), ages 37–69. In total, at least 3.5% of critically ill patients carried known or new deleterious variants at the 8 identified loci. pDCs from an AR IRF7-deficient patient produced no detectable type I or III IFNs upon SARS-CoV-2 infection in vitro. This confirmed the generalizable principle: IRF7-mediated IFN amplification is non-redundant for defense against multiple severe respiratory viruses, not just influenza.

Tissue-specific and epigenetic aspects

A 2025 bioinformatics + immunohistochemistry study in Journal of Orthopaedic Surgery and Research (n=15 young patients aged <45 years vs n=15 aging patients aged ≥45 years with meniscus injury) identified IRF7 and SPHK1 as the two most downregulated inflammation-related genes in aging meniscal tissue, validated at both the transcriptomic level (RNA-seq training dataset, GSE191157 testing dataset) and protein level (IHC, p<0.0001 for IRF7 IOD) 6. Machine-learning models (SVM ROC-AUC=0.73; ANN ROC-AUC=0.79) suggest these two genes have diagnostic utility for aging meniscus injury. The orthopaedic context is narrow and the sample size is small; the study does not establish causal direction of IRF7 silencing in inflammaging, nor is it clear whether findings generalize beyond meniscal tissue. Weight accordingly. needs-replication

Pathway membership

  • type-i-interferon-signaling — central node; IRF7 is the primary IFNA transactivator and a positive feedback element of the entire pathway
  • innate-immune-signaling — downstream of TLR7, TLR9, RIG-I/MDA5, cGAS-STING (cell-type dependent)
  • jak-stat-signaling — indirect participant; ISG status means JAK-STAT signaling induces IRF7 expression

Key interactors

  • tbk1 — primary activating kinase; phosphorylates Ser477/479
  • ikbke — co-activating kinase with TBK1; also phosphorylates Ser477/479
  • irf3 — heterodimerization partner; IRF3:IRF7 heterodimers are critical for amplified IFNB1 responses
  • myd88 — adaptor for TLR7/9 → IRF7 in pDCs (TLR9-MyD88-IRF7 is the primary pDC viral-sensing axis)
  • traf6 — downstream of MyD88; bridges to TBK1 activation
  • ticam1 (TRIF) / TICAM2 — adaptor proteins for TLR3/4 → TBK1 in non-pDC cell types

Druggability (aging context)

druggability-tier: 4 — IRF7 is a transcription factor; no approved direct IRF7 modulator exists and TF active sites are generally undruggable. Upstream kinases TBK1 and IKKε are the tractable pharmacological nodes:

  • TBK1 inhibitors (amlexanox, BX795, MRT67307, compound II) are investigational tools; none approved. In an aging context, systemic TBK1 inhibition would suppress antiviral IFN responses — a significant safety liability.
  • IRF7 enhancement (to compensate for age-related decline) has no approved approach; conceptually, upstream innate immune priming (adjuvants, pattern-recognition receptor agonists) could activate the pathway.

The aging-intervention question is directionally complex: stimulus-evoked pDC IFN-α declines with frailty (calling for IRF7 enhancement or pDC functional restoration), while simultaneously general pro-inflammatory cytokine levels increase (calling for anti-inflammatory strategies). Interventions targeting IRF7 directly would risk modulating both arms simultaneously. Upstream innate immune priming (adjuvants, TLR agonists) could restore stimulus-evoked IFN-α responses without requiring direct IRF7 targeting. Intervention design requires cell-type-specific and stimulus-context-specific strategies. no-mechanism

Limitations and gaps

  • #gap/needs-canonical-id — GenAge HAGR entry for IRF7 not confirmed; genage-id left null.
  • #gap/needs-replication — IRF7 protein level in aged human pDCs: neither Sugihara 2026 nor Wu 2025 directly measured IRF7 protein; expression changes are inferred from functional assays and mRNA data.
  • #gap/no-mechanism — the molecular basis for stimulus-evoked pDC IFN-α decline with aging/frailty is not established; Sugihara 2026 is cross-sectional and cannot distinguish cause from consequence.
  • #gap/needs-human-replication — aged-mouse IFN response data (Wu 2025, GeroScience, C57BL/6J 70-wk vs 12-wk) has not been directly validated in human elderly cohorts with matched viral challenge protocols.
  • #gap/no-mechanism — IRF7 epigenetic silencing in meniscus/other tissues: causal direction and generalizability to systemic inflammaging unknown.

Footnotes

Footnotes

  1. doi:10.1186/s12979-026-00555-x · Sugihara Y et al. · cross-sectional cohort · Immunity & Ageing 2026 · n=141 Japanese elderly (mean age 79.5±5.3 yr, excluding chronic disease); 76 robust, 52 pre-frail, 13 frail (J-CHS criteria); H1N1-stimulated pDC IFN-α+pDC declines with frailty progression; OR 0.212 (95% CI 0.051–0.895) frail vs robust in fully adjusted model · PDF verified 2026-05-13 ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. doi:10.1007/s11357-025-01892-3 · PMID 40987991 · Wu W et al. · in-vivo (mouse) · GeroScience 2025 · n: young 12-wk vs old 70-wk C57BL/6J mice, influenza A PR8 i.n.; lower lung type I IFN at 3 dpi, higher viral loads in old mice; elevated Irf7 mRNA (scRNA-seq) at 7 dpi in aged lung immune cells; PDF unavailable (hybrid OA; download failed) · abstract verified via PubMed efetch 2026-05-13 ↩ ↩2 ↩3 ↩4 ↩5

  3. doi:10.1126/science.aaa1578 · PMID 25814066 · Ciancanelli MJ et al. (Casanova lab) · n=1 patient (compound-heterozygous null IRF7 mutations) + in-vitro mechanistic follow-up in leukocytes, pDCs, fibroblasts, iPSC-derived pulmonary epithelial cells · Science 2015 · 455 citations · PDF not available via archive (failed download; abstract verified via PubMed efetch) ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  4. doi:10.1126/science.abd4570 · PMC7857407 · Zhang Q et al. (Casanova lab + consortium) · n=659 critical COVID-19, 534 asymptomatic/mild controls · genetic association + functional validation · Science 2020 · IRF7: 8 patients with deleterious variants (AR and AD forms), ages 37–69; pDCs from AR IRF7-deficient patient produced no detectable type I or III IFN to SARS-CoV-2 in vitro · 2359 citations · PDF verified 2026-05-13 ↩ ↩2 ↩3

  5. UniProt Q92985 (IRF7_HUMAN), Swiss-Prot/manually reviewed · accessed 2026-05-13 · confirms domain map, PTM sites (Ser477/479 TBK1/IKKε; Lys92 acetylation), subcellular localization, and functional summary ↩ ↩2 ↩3 ↩4

  6. doi:10.1186/s13018-025-06518-0 · Yang S et al. · bioinformatics + IHC · J Orthop Surg Res 2025 · n=15 young (<45 yr) vs 15 aging (≥45 yr) meniscus injury patients; IRF7 and SPHK1 downregulated at transcript and protein level in aging tissue (IHC p<0.0001); SVM ROC-AUC=0.73, ANN ROC-AUC=0.79 · low-tier journal for IFN biology claim; weight accordingly · PDF verified 2026-05-13 ↩

Graph View

Backlinks